atrasentan has been researched along with Angiogenesis, Pathologic in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (85.71) | 29.6817 |
| 2010's | 1 (14.29) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Castelo, B; Espinosa, E; Merino, M; Pinto, A; Redondo, A; Zamora, P | 1 |
| Bagnato, A; Cirilli, A; Muller, A; Natali, PG; Nicotra, MR; Salani, D; Simeone, P; Venuti, A | 1 |
| Bagnato, A; Di Castro, V; Natali, PG; Nicotra, MR; Rosanò, L; Salani, D; Spinella, F; Venuti, A | 1 |
| Carducci, MA; Lassiter, LK | 1 |
| Bagnato, A; Di Castro, V; Natali, PG; Rosanò, L; Spinella, F | 1 |
| Carducci, M; Jimeno, A | 1 |
| Akhavan, A; Bies, RR; Guruli, G; McHugh, KH; Nelson, JB; Pflug, BR; Strychor, SA; Zamboni, WC | 1 |
3 review(s) available for atrasentan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Targeting the endothelin axis in prostate carcinoma.
Topics: Atrasentan; Bone and Bones; Carcinoma; Cell Proliferation; Clinical Trials as Topic; Endothelins; Gene Expression Regulation, Neoplastic; Humans; Male; Neoplasm Invasiveness; Neoplasm Metastasis; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines | 2012 |
Endothelin receptor antagonists in the treatment of prostate cancer.
Topics: Androgen Antagonists; Apoptosis; Atrasentan; Bone Neoplasms; Bosentan; Clinical Trials as Topic; Disease Progression; Drug Resistance, Neoplasm; Endothelin Receptor Antagonists; Endothelins; Forecasting; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrimidines; Pyrrolidines; Receptors, Endothelin; Sulfonamides; Treatment Outcome | 2003 |
Atrasentan: a novel and rationally designed therapeutic alternative in the management of cancer.
Topics: Apoptosis; Atrasentan; Bone Neoplasms; Clinical Trials as Topic; Disease Progression; Endothelins; Humans; Male; Neovascularization, Pathologic; Prostatic Neoplasms; Pyrrolidines | 2005 |
4 other study(ies) available for atrasentan and Angiogenesis, Pathologic
| Article | Year |
|---|---|
Growth inhibition of cervix carcinoma cells in vivo by endothelin A receptor blockade.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Atrasentan; Cell Division; Drug Synergism; Endothelin Receptor Antagonists; Female; Humans; Mice; Mice, Nude; Neovascularization, Pathologic; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Tumor Cells, Cultured; Uterine Cervical Neoplasms; Xenograft Model Antitumor Assays | 2002 |
Therapeutic targeting of the endothelin a receptor in human ovarian carcinoma.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Division; Drug Synergism; Endothelial Growth Factors; Endothelin Receptor Antagonists; Female; Growth Inhibitors; Humans; Intercellular Signaling Peptides and Proteins; Lymphokines; Mice; Mice, Nude; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factors; Xenograft Model Antitumor Assays | 2003 |
Therapeutic targeting of the endothelin-A receptor in human ovarian carcinoma: efficacy of cytotoxic agents is markedly enhanced by co-administration with atrasentan.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Atrasentan; Cell Line, Tumor; Cisplatin; Endothelin A Receptor Antagonists; Female; Humans; Injections, Intraperitoneal; Injections, Intravenous; Mice; Mice, Nude; Neoplasm Invasiveness; Neovascularization, Pathologic; Ovarian Neoplasms; Paclitaxel; Pyrrolidines; Receptor, Endothelin A; Time Factors; Xenograft Model Antitumor Assays | 2004 |
Endothelin receptor A blockade enhances taxane effects in prostate cancer.
Topics: Animals; Apoptosis; Atrasentan; Bridged-Ring Compounds; Cell Survival; Endothelin A Receptor Antagonists; Humans; Ki-67 Antigen; Male; Mice; Neoplasm Transplantation; Neovascularization, Pathologic; Platelet Endothelial Cell Adhesion Molecule-1; Prostatic Neoplasms; Pyrrolidines; Taxoids | 2006 |